Acute Ventricular Rate Control in Atrial Fibrillation With Rapid Ventricular Response
In atrial fibrillation with rapid ventricular response (RVR), intravenous diltiazem should be initiated for acute rate control when hemodynamic stability is present and moderate/severe LV systolic dysfunction is not present. [1] An intravenous amiodarone infusion (drip) should be started for acute rate control when the patient is critically ill and/or in decompensated heart failure and beta blockers and nondihydropyridine calcium channel blockers are ineffective or contraindicated. [1]
Diltiazem Initiation Criteria
Diltiazem (or verapamil or beta blocker) is recommended for acute rate control when all of the following are present: [1]
- Hemodynamic stability is present. [1]
- Moderate or severe LV systolic dysfunction is absent. [1]
- Nondihydropyridine calcium channel blocker administration is supported by guideline criteria, including EF >40% for diltiazem/verapamil use in this setting. [1]
Amiodarone Drip Initiation Criteria
Intravenous amiodarone may be considered for acute rate control when all of the following are present: [1]
- The patient is critically ill and/or in decompensated heart failure. [1]
- Beta blockers and nondihydropyridine calcium channel blockers are ineffective or contraindicated. [1]
Key Exclusion Criteria for Diltiazem
Nondihydropyridine calcium channel blockers (diltiazem and verapamil) should not be administered in atrial fibrillation with RVR and known moderate or severe LV systolic dysfunction, with or without decompensated heart failure. [1]
Practical Decision Framework for Starting Therapy
Rate-control drug selection for AF with RVR should follow an acute algorithm: [1]
- First-line for hemodynamically stable patients: beta blockers or nondihydropyridine calcium channel blockers (including diltiazem) with EF >40%. [1]
- Second-line when beta blockers and nondihydropyridine calcium channel blockers are ineffective or contraindicated: digoxin can be considered for acute rate control. [1]
- Escalation when critically ill or in decompensated heart failure and beta blockers and nondihydropyridine calcium channel blockers are ineffective or contraindicated: intravenous amiodarone may be considered. [1]
Hemodynamic Safety Considerations
Advanced-life-support guidance notes that AV nodal blocking agents (including diltiazem) and intravenous amiodarone can be problematic in the presence of preexcitation because of concern for accelerated ventricular response. [2]
Dosing/Administration Details
The question-specific guideline recommendations address when to initiate therapy but do not provide infusion initiation parameters in the cited sections. [1] Dosing and infusion protocols should follow local ACLS/ED order sets and institutional practice for intravenous diltiazem and intravenous amiodarone. [1][2]